Key Highlights

● SELLAS priced a $150 million offering at $13.00 a share.

● The stock closed at $14.86, above the offering price.

● Phase 3 REGAL showed a hazard ratio for death of 0.59.

● Median overall survival was 24.0 months versus 14.7 months in the control group.

SELLAS Life Sciences (NASDAQ:SLS) priced a $150 million share offering below its prior close after a spectacular two-day rally on Phase 3 leukemia data, and its shares gave back part of those gains.

The offering

SELLAS Life Sciences priced a $150 million public offering at $13.00 a share. That was below the stock's previous closing price. J.P. Morgan and TD Cowen ran the books, and underwriters have an option to buy up to $22.5 million of additional shares.

The stock fell on Thursday, November 19, closing at $14.86. Even after the fall, the shares finished above the offering price.

The data that sparked the rally

The offering followed a remarkable run. On Tuesday, November 17, SELLAS reported positive topline results from its Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia, or AML. The trial showed a hazard ratio for death of 0.59, with a p-value of 0.035, and median overall survival of 24.0 months, compared with 14.7 months in the control group.

A hazard ratio below 1 means patients on the treatment had a lower risk of death over the study period than those in the comparison group. A p-value below 0.05 is typically read as statistically significant. Median overall survival is the point at which half of the patients in a group are still alive.

The stock rocketed on November 17 and kept soaring the next day.

Why companies sell stock after good news

For small biotech companies, raising money after strong data is common. A higher share price means the company can raise more cash while issuing fewer new shares, which limits dilution for existing holders. Biotechs often need substantial funding to complete regulatory filings, prepare Manufacturing and plan for a commercial launch.

The trade-off is that new shares sold at a discount to the Market Price tend to pull the stock lower in the short term. That pattern played out on Thursday.

Market backdrop

The pullback coincided with a sharp market decline. The Russell 2000 fell 59.20 points to 2,655.11, and the S&P SmallCap 600 closed at 1,635.57, the worst of the major indexes. The S&P 500 dropped 147.80 points to 7,175.83 for a sixth straight loss, its longest losing streak since April 2024. The Dow lost 1,101.11 points to close below 50,000. Fed minutes released on Wednesday showed nearly all officials see further rate increases as likely needed, according to market data, and weekly jobless claims rose to 203,000.

Health care was among the weaker sectors, although Insmed (NASDAQ:INSM) jumped on an unconfirmed media report that Sanofi (NASDAQ:SNY) was studying a possible acquisition; no deal has been agreed.

What to watch

Investors will look for SELLAS's next regulatory steps for galinpepimut-S, including any plans to seek approval and the timing. Fuller data from the REGAL study, including details beyond the topline results, will draw close scrutiny from doctors and investors alike. The company's use of the new cash will be watched too. The stock has been one of the more volatile names on the Russell 2000 this week.